109 related articles for article (PubMed ID: 8602984)
81. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells in multiple myeloma: the issue of safety.
Sica S; Sorá F; Chiusolo P; Cicconi S; Piccirillo N; Cattani P; Laurenti L; Leone G
Exp Hematol; 2001 Jan; 29(1):1-2. PubMed ID: 11234735
[No Abstract] [Full Text] [Related]
82. The CD34+Thy1+ cell population: are they all stem cells?
McNiece I
Exp Hematol; 2000 Dec; 28(12):1312-4. PubMed ID: 11188921
[No Abstract] [Full Text] [Related]
83. Marker gene transfer into leukapheresis preparations containing hematopoietic progenitor cells: application in high-dose therapy rescued by reinfusion of peripheral blood hematopoietic progenitors in patients with multiple myeloma.
Herrmann F; Kiehntopf M; Brach MA; Carstanjen D; von Schilling C
J Mol Med (Berl); 1995 Apr; 73(4):197-203. PubMed ID: 7627640
[No Abstract] [Full Text] [Related]
84. Recruitment of CD34+ cells during large-volume leukapheresis.
Cull G; Cannell P
Transfusion; 1997 Jun; 37(6):672-3. PubMed ID: 9191835
[No Abstract] [Full Text] [Related]
85. Are CD34+ selected cells the better choice for grafting?
Körbling M
Cancer Invest; 1996; 14(6):640-1. PubMed ID: 8951368
[No Abstract] [Full Text] [Related]
86. Processing of hematopoietic stem cell components for transplantation: variations in current practice.
Rowley SD
Transfusion; 1998 Jan; 38(1):1-4. PubMed ID: 9482385
[No Abstract] [Full Text] [Related]
87. Isolation of hematopoietic stem cells from heparinized cadaveric multiple organ donors: potential clinical implications.
Marlicz W; Paczkowski M; Kijowski J; Machalinski B; Gontarewicz A; Paczkowska E; Zukowski M; Turkiewicz W; Bohatyrewicz R; Czajkowski Z; Ostrowski M; Ratajczak MZ
Transplant Proc; 1999 Aug; 31(5):2099-101. PubMed ID: 10455982
[No Abstract] [Full Text] [Related]
88. Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation.
Dahi PB; Lin A; Scordo M; Flynn JR; Devlin SM; Ruiz JD; DeRespiris L; Carlow D; Cho C; Lahoud OB; Perales MA; Sauter CS; Boelens JJ; Admiraal R; Giralt SA; Shah GL
Transplant Cell Ther; 2022 Aug; 28(8):485.e1-485.e6. PubMed ID: 35545213
[TBL] [Abstract][Full Text] [Related]
89. Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma.
Dahi PB; Lee J; Devlin SM; Ruiz J; Maloy M; Rondon-Clavo C; Petrlik E; Tamari R; Shah G; Scordo M; Matasar MJ; Hamlin PA; Papadopoulos E; Jakubowski AA; Perales MA; Moskowitz CH; Sauter CS; Giralt SA
Blood Adv; 2021 Jun; 5(12):2608-2618. PubMed ID: 34152404
[TBL] [Abstract][Full Text] [Related]
90. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Dahi PB; Tamari R; Devlin SM; Maloy M; Bhatt V; Scordo M; Goldberg J; Zelenetz AD; Hamlin PA; Matasar MJ; Maragulia J; Giralt SA; Perales MA; Moskowitz CH; Sauter CS
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2004-9. PubMed ID: 25175794
[TBL] [Abstract][Full Text] [Related]
91. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study.
Chabannon C; Cornetta K; Lotz JP; Rosenfeld C; Shlomchik M; Yanovitch S; Marolleau JP; Sledge G; Novakovitch G; Srour EF; Burtness B; Camerlo J; Gravis G; Lee-Fischer J; Faucher C; Chabbert I; Krause D; Maraninchi D; Mills B; Kunkel L; Oldham F; Blaise D; Viens P
Br J Cancer; 1998 Oct; 78(7):913-21. PubMed ID: 9764583
[TBL] [Abstract][Full Text] [Related]
92. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
93. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
94. Transplantation of CD34+ hematopoietic progenitor cells.
Berenson RJ; Shpall EJ; Auditore-Hargreaves K; Heimfeld S; Jacobs C; Krieger MS
Cancer Invest; 1996; 14(6):589-96. PubMed ID: 8951362
[TBL] [Abstract][Full Text] [Related]
95. CD34 cell separation: from basic research to clinical applications.
Nadali G; de Wynter EA; Testa NG
Int J Clin Lab Res; 1995; 25(3):121-7. PubMed ID: 8562973
[TBL] [Abstract][Full Text] [Related]
96. G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma.
Mahé B; Milpied N; Hermouet S; Robillard N; Moreau P; Letortorec S; Rapp MJ; Bataille R; Harousseau JL
Br J Haematol; 1996 Feb; 92(2):263-8. PubMed ID: 8602984
[TBL] [Abstract][Full Text] [Related]
97. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
